| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/07/2005 | WO2005060949A2 Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition |
| 07/07/2005 | WO2005060948A1 Use of fepradinol for the production of a pharmaceutical composition for the treatment of rosacea |
| 07/07/2005 | WO2005060947A2 Agonist and antagonist ligands of the nociceptin receptor |
| 07/07/2005 | WO2005060946A1 Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass |
| 07/07/2005 | WO2005060945A2 Intranasal compositions comprising zolpidem |
| 07/07/2005 | WO2005060942A1 Extended release pharmaceutical composition of metformin |
| 07/07/2005 | WO2005060941A1 Extended release antibiotic composition |
| 07/07/2005 | WO2005060940A2 Method for the production of a solid, orally applicable pharmaceutical composition |
| 07/07/2005 | WO2005060939A2 Controlled-release pharmaceutical formulation |
| 07/07/2005 | WO2005060938A1 Process for producing pellets for pharmaceutical compositions |
| 07/07/2005 | WO2005060936A1 Cefdinir oral suspension |
| 07/07/2005 | WO2005060935A1 Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle |
| 07/07/2005 | WO2005060933A1 Ophthalmic compositions containing a polysaccharide/borate gelling system |
| 07/07/2005 | WO2005060922A1 Cosmetic composition containing a polyorganosiloxane polymer |
| 07/07/2005 | WO2005060768A1 Nutritional composition for wound healing |
| 07/07/2005 | WO2005060749A1 Substituted arylpyrazoles as parasiticidal agents |
| 07/07/2005 | WO2005060748A1 Fungicide |
| 07/07/2005 | WO2005060711A2 Methods of treating a disorder |
| 07/07/2005 | WO2005060694A2 Treatment of neurologic disorders with inhibitors of 11beta-hsd1 |
| 07/07/2005 | WO2005060693A2 9-desoxoerythromycin compounds as prokinetic agents |
| 07/07/2005 | WO2005060665A2 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
| 07/07/2005 | WO2005060663A2 Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis |
| 07/07/2005 | WO2005060661A2 Methods and materials for assessing prostate cancer therapies |
| 07/07/2005 | WO2005060654A2 Mitotic kinesin inhibitors |
| 07/07/2005 | WO2005060571A2 Antiprotozoal imidazopyridine compounds |
| 07/07/2005 | WO2005060542A2 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| 07/07/2005 | WO2005060540A2 Norethindrone sustained release transdermal formulation |
| 07/07/2005 | WO2005060361A2 Pharmaceutical formulations for itraconazole |
| 07/07/2005 | WO2005060342A2 Cysteamine compounds for treating allergy |
| 07/07/2005 | WO2005060330A2 Freeze-dried vaccine adjuvant |
| 07/07/2005 | WO2005051323A3 Vitamin d analogs for obesity prevention and treatment |
| 07/07/2005 | WO2005049593A3 N-acylsulfonamide apoptosis promoters |
| 07/07/2005 | WO2005047258A3 Methods and compositions for selectin inhibition |
| 07/07/2005 | WO2005047257A3 Methods and compositions for selectin inhibition |
| 07/07/2005 | WO2005046637A3 Pharmaceutical formulations employing short-chain sphingolipids and their use |
| 07/07/2005 | WO2005042521A3 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 07/07/2005 | WO2005041960A3 Neuromuscular blocking agents and antagonists thereof |
| 07/07/2005 | WO2005040160A3 Processes for preparation of ziprasidone |
| 07/07/2005 | WO2005040045A3 Method for the production of trans- or cis-diammoniumdichlorodihydroxoplatinum (iv) and use thereof for the production of pharmaceutical agent |
| 07/07/2005 | WO2005037839A8 Norcantharidin derivative compounds, method for the production thereof, compositions containing said compounds and the use thereof |
| 07/07/2005 | WO2005037779A3 Novel dipeptidyl peptidase iv inhibitors used for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases |
| 07/07/2005 | WO2005037346A3 Method for providing long-lasting pain relief through intrathecal administration of civamide |
| 07/07/2005 | WO2005037052A3 Binding assay with labelled bispidine variant |
| 07/07/2005 | WO2005034869A3 Compounds and compositions as protein kinase inhibitors |
| 07/07/2005 | WO2005034849A3 Methods for identifying improved, non-sedating alpha-2 agonists |
| 07/07/2005 | WO2005032471A3 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| 07/07/2005 | WO2005030200A8 Remedy for autoimmune diseases |
| 07/07/2005 | WO2005027988A3 Bone cement compositions having fiber-reinforcement and/or increased flowability |
| 07/07/2005 | WO2005027719A3 Methods and systems for identifying predisposition to the placebo effect |
| 07/07/2005 | WO2005027663A3 Compositions comprising oligosaccharides |
| 07/07/2005 | WO2005023304A3 Antimalarial compositions and manufacturing process thereof |
| 07/07/2005 | WO2005021025A3 MODULATION OF β-CATENIN/TCF ACTIVATED TRANSCRIPTION |
| 07/07/2005 | WO2005020970A3 Protease inhibitor compositions for prevention and treatment of skin conditions |
| 07/07/2005 | WO2005018582A3 Compositions containing topical active agents and pentylene glycol |
| 07/07/2005 | WO2005016288A3 Methods and compositions for treatment of viral diseases |
| 07/07/2005 | WO2005016276A3 Sigma-1 receptor ligand with acetylcholinesterase inhibition properties |
| 07/07/2005 | WO2005016265A3 Method for promoting bone growth |
| 07/07/2005 | WO2005014776A3 Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| 07/07/2005 | WO2005011586A3 Treatment and preventi0n of cardiovascular events |
| 07/07/2005 | WO2005009954A3 Method for modulating calcium ion-release-activated calcium ion channels |
| 07/07/2005 | WO2005007082A8 Treatment of chronic bacterial infection |
| 07/07/2005 | WO2005007080A3 Methods and compositions for delivery of catecholic butanes for treatment of tumors |
| 07/07/2005 | WO2005005447A3 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| 07/07/2005 | WO2004103304A3 Treatment of t-cell mediated diseases |
| 07/07/2005 | WO2004100868A3 Method of treating transplant rejection |
| 07/07/2005 | WO2004098516A3 Cyclic derivatives as modulators of chemokine receptor activity |
| 07/07/2005 | WO2004085666A3 Secreted proteins |
| 07/07/2005 | WO2004082822A3 Methods for isolating crystalline form i of 5-azacytidine |
| 07/07/2005 | WO2004075844A3 Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
| 07/07/2005 | WO2004073605A3 Skin peeling composition and method |
| 07/07/2005 | WO2004060369A8 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes |
| 07/07/2005 | WO2004058704A3 Quinazolinones as potassium channel modulators |
| 07/07/2005 | WO2004046160A8 Amino-lna, thio-lna and alpha-l-oxy-ln |
| 07/07/2005 | WO2004034957A3 Methods for treatment of helicobacter pylori-associated disorders |
| 07/07/2005 | WO2004017914A8 Inhalation composition |
| 07/07/2005 | WO2004004779A8 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 07/07/2005 | WO2003089583A3 Tissue specific genes and gene clusters |
| 07/07/2005 | WO2003063771A3 N4-acylcytosine nucleosides for treatment of viral iinfections |
| 07/07/2005 | WO2003053360A3 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 07/07/2005 | US20050148910 Apparatus having a skin-contactable element containing an agent |
| 07/07/2005 | US20050148908 Apparatus containing a receiving element for treatment of skin |
| 07/07/2005 | US20050148907 Treatment of skin using a benefit agent and an apparatus |
| 07/07/2005 | US20050148906 Apparatus for treatment of the skin having a signaling marker |
| 07/07/2005 | US20050148833 Apparatus containing a sensing element for the treatment of skin |
| 07/07/2005 | US20050148779 Carvedilol monocitrate monohydrate |
| 07/07/2005 | US20050148777 (2R)-6-chloro-7-isobutyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid; cyclooxygenase-2 mediated disorders |
| 07/07/2005 | US20050148772 Methods and compositions for detecting polynucleotide duplex damage and errors |
| 07/07/2005 | US20050148768 Cobalt-porphyrin complexes and use thereof as an anti-obesity agent |
| 07/07/2005 | US20050148767 Self-cross-linked alkyl cellulose |
| 07/07/2005 | US20050148675 Efficient and inexpensive method to prepare ubiquinone precursors using benzenoid precursor with retention of the double bond stereochemistry; industrial scale; carbolumination of alkynes |
| 07/07/2005 | US20050148674 the ability of people to consume alcohol while reducing hangovers or other effects of intoxication by administering an effective amount of a cysteamine |
| 07/07/2005 | US20050148673 Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition |
| 07/07/2005 | US20050148672 reacting methyl bromide and 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(trifluoromethyl) phenol; formation of (3R)-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-N,N-diisopropyl-N-methyl-3-phenylpropan-1-aminium bromide; asthma, chronic obstructive pulmonary disorder, allergic and infectious rhinitis |
| 07/07/2005 | US20050148671 (2S)-amino(phenyl)acetic acid and derivatives as alpha2delta voltage-gated calcium channel ligands |
| 07/07/2005 | US20050148669 Avoid premature destruction of amino acids by providing esterified amino acids as nutrient supplements; more fat soluble; bioavailability; enhanced lipophillic nature; oral administration; methods of conducting business activitiesrelating to the designing, manufacture, packaging, marketing, distributing |
| 07/07/2005 | US20050148668 Lipoxin compounds and their use in treating cell proliferative disorders |
| 07/07/2005 | US20050148667 Highly pure (R,R)-formoterol L-tartrate composition obtained by crystallizing a first polymorph of (R,R)-formoterol L-tartrate from aqueous isopropyl alcohol |
| 07/07/2005 | US20050148666 Treating diabetes by administering a diacylglycerol especially of omega 3 unsaturated fatty acids such as glycerol dilinolenate; diacylglycerols have the lipid catabolism activating effect in the small intestine and lipid metabolism improving effect |
| 07/07/2005 | US20050148665 caged non-steroidal ecdysome memetic; water soluble and accumulates in a host cell; biologically inactive until it is photochemically transformed by light |
| 07/07/2005 | US20050148664 therapy of NF-kappaB mediated diseases; mitochondrial diseases; transplantation medicine |